Therapy Areas: Infectious Diseases
Memo Therapeutics AG Initiates Phase 1 Clinical Study of MTX-005 Against BK Virus Infection
1 June 2022 - - Switzerland-based antibody discovery and development company Memo Therapeutics AG has initiated a phase 1 clinical study targeting BK polyomavirus infection in renal transplant patients, the company said.

The phase 1, single-blind, partially randomized, placebo-controlled study will assess safety, tolerability, and pharmacokinetics of single and multiple ascending intravenous doses of MTX-005 in up to 56 healthy adult volunteers.

MTX-005 is a therapeutic antibody candidate that was identified through the screening of a vast number of kidney transplant patients infected with BK virus to find those few with an eradicating antibody response against the virus.

Selected from thousands of BKV-specific antibodies, MTX-005 completely neutralizes all strains of BKV at extremely low concentrations.

BKV infection poses a significant threat in kidney transplantation. Normally dormant, the immunosuppression needed for transplant survival can trigger reactivation of BKV in 40 to 50% of kidney transplant recipients.

Up to 10% of these cases can progress to BKV associated nephropathy, which poses a serious threat to the transplant.

There is currently no disease modifying therapy available except for the lowering of immunosuppression. However, this significantly increases the risk of a graft rejection reaction, leading to impaired functionality and longevity, or graft failure.

Memo Therapeutics AG is in the field of antibody discovery and immune repertoire analysis.

The company's antibody discovery platform uses microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency, and sensitivity.

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects.

The company's current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Schlieren/Zurich, Switzerland.
Login
Username:

Password: